AER 1433216, is a clinical case, received on 09/Jul/2014 from an other healthcare professional via company 
representatives and concerns a female patient of unknown age who developed progressive multifocal 
leukoencephalopathy while being enrolled in unknown study and treated with rituximab.
No medical history, concurrent condition, concomitant medications or past drugs were reported.
On an unspecified date, the patient started therapy with rituximab (dosing regimen not reported) for unknown 
indication. Later, it was reported that the patient developed PML (Progressive multifocal leukoencephalopathy).
At the time of this report, the outcome of the event progressive multifocal leukoencephalopathy was not reported 
and it was unknown whether therapy with rituximab was ongoing or not.
The reporter considered the event progressive multifocal leukoencephalopathy as related to rituximab.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 20 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
No further information was provided.